For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
According to our (Global Info Research) latest study, the global Glucagon Like Peptide-1 (GLP-1) Agonists market size was valued at USD 9071.4 million in 2022 and is forecast to a readjusted size of USD 20980 million by 2029 with a CAGR of 12.7% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.
This report is a detailed and comprehensive analysis for global Glucagon Like Peptide-1 (GLP-1) Agonists market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Glucagon Like Peptide-1 (GLP-1) Agonists market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Glucagon Like Peptide-1 (GLP-1) Agonists market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Glucagon Like Peptide-1 (GLP-1) Agonists
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Glucagon Like Peptide-1 (GLP-1) Agonists market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, AstraZeneca, Eli Lily, GSK and Sanofi, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Glucagon Like Peptide-1 (GLP-1) Agonists market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Exenatied
- Liraglutide
- Lixisenatide
- Albiglutide
- Dulaglutide
Market segment by Application
- Hospital
- Pharmacy
- Other
Major players covered
- Novo Nordisk
- AstraZeneca
- Eli Lily
- GSK
- Sanofi
- Bristol-Myers Squibb
- Amylin
Market segment by region, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Glucagon Like Peptide-1 (GLP-1) Agonists product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, with price, sales, revenue and global market share of Glucagon Like Peptide-1 (GLP-1) Agonists from 2018 to 2023.
Chapter 3, the Glucagon Like Peptide-1 (GLP-1) Agonists competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Glucagon Like Peptide-1 (GLP-1) Agonists breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Glucagon Like Peptide-1 (GLP-1) Agonists market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Glucagon Like Peptide-1 (GLP-1) Agonists.
Chapter 14 and 15, to describe Glucagon Like Peptide-1 (GLP-1) Agonists sales channel, distributors, customers, research findings and conclusion.